Literature DB >> 17868773

Stromogenic prostatic carcinoma pattern (carcinomas with reactive stromal grade 3) in needle biopsies predicts biochemical recurrence-free survival in patients after radical prostatectomy.

Nobuyuki Yanagisawa1, Rile Li, David Rowley, Hao Liu, Dov Kadmon, Brian J Miles, Thomas M Wheeler, Gustavo E Ayala.   

Abstract

We previously reported that reactive stromal grading in radical prostatectomies is a predictor of recurrence and that reactive stromal grading 0 and 3 are associated with lower biochemical recurrence-free survival rates than reactive stromal grading 1 and 2. We explored the prognostic significance of reactive stromal grading in preoperative needle biopsies. At Baylor College of Medicine, 224 cases of prostatic carcinoma were diagnosed by needle biopsy. Reactive stromal grading was evaluated on hematoxylin-eosin (H&E)-stained sections on the basis of previously described criteria: grade 0, with 0% to 5% reactive stroma; grade 1, 6% to 15%; grade 2, 16% to 50%; grade 3, 51% to 100%, or at least a 1:1 ratio between glands and stroma. Kaplan-Meier and Cox proportional hazard analyses were used. Reactive stromal grading distribution was as follows: reactive stromal grading 0, 1 case (0.5%); reactive stromal grading 1, 149 cases (66.5%); reactive stromal grading 2, 59 cases (26.3%); reactive stromal grading 3, 15 cases (6.7%). Reactive stromal grading in biopsies was correlated with adverse clinicopathologic parameters in the prostatectomy. Patients with reactive stromal grading 1 and 2 had better survival than those with 0 and 3 (P = .0034). Reactive stromal grading was an independent predictor of recurrence (hazard ratio = 1.953; P = .0174). Reactive stromal grading is independent of Gleason 4 + 3 and 3 + 4 in patients with a Gleason score of 7. Quantitation of reactive stroma and recognition of the stromogenic carcinoma in H&E-stained biopsies is useful to predict biochemical recurrence in prostate carcinoma patients independent of Gleason grade and prostate-specific antigen.

Entities:  

Mesh:

Year:  2007        PMID: 17868773     DOI: 10.1016/j.humpath.2007.04.008

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  37 in total

Review 1.  Interaction of prostate carcinoma-associated fibroblasts with human epithelial cell lines in vivo.

Authors:  Takeshi Sasaki; Omar E Franco; Simon W Hayward
Journal:  Differentiation       Date:  2017-07-20       Impact factor: 3.880

2.  Endogenous versus tumor-specific host response to breast carcinoma: a study of stromal response in synchronous breast primaries and biopsy site changes.

Authors:  Julie M Wu; Andrew H Beck; Lisa L Pate; Daniela Witten; Shirley X Zhu; Kelli D Montgomery; Kimberly H Allison; Matt van de Rijn; Robert B West
Journal:  Clin Cancer Res       Date:  2010-11-22       Impact factor: 12.531

Review 3.  Heralding a new paradigm in 3D tumor modeling.

Authors:  Eliza L S Fong; Daniel A Harrington; Mary C Farach-Carson; Hanry Yu
Journal:  Biomaterials       Date:  2016-09-02       Impact factor: 12.479

Review 4.  The reactive stroma microenvironment and prostate cancer progression.

Authors:  David A Barron; David R Rowley
Journal:  Endocr Relat Cancer       Date:  2012-10-30       Impact factor: 5.678

5.  RUNX1 is essential for mesenchymal stem cell proliferation and myofibroblast differentiation.

Authors:  Woosook Kim; David A Barron; Rebeca San Martin; Keith S Chan; Linda L Tran; Feng Yang; Steven J Ressler; David R Rowley
Journal:  Proc Natl Acad Sci U S A       Date:  2014-10-13       Impact factor: 11.205

Review 6.  Therapeutic targeting of the prostate cancer microenvironment.

Authors:  Maria Karlou; Vassiliki Tzelepi; Eleni Efstathiou
Journal:  Nat Rev Urol       Date:  2010-09       Impact factor: 14.432

7.  The proportion of tumour cells is an independent predictor for survival in colorectal cancer patients.

Authors:  N P West; M Dattani; P McShane; G Hutchins; J Grabsch; W Mueller; D Treanor; P Quirke; H Grabsch
Journal:  Br J Cancer       Date:  2010-04-20       Impact factor: 7.640

8.  Stromal PDGFRbeta expression in prostate tumors and non-malignant prostate tissue predicts prostate cancer survival.

Authors:  Christina Hägglöf; Peter Hammarsten; Andreas Josefsson; Pär Stattin; Janna Paulsson; Anders Bergh; Arne Ostman
Journal:  PLoS One       Date:  2010-05-20       Impact factor: 3.240

9.  Pathway biomarker profiling of localized and metastatic human prostate cancer reveal metastatic and prognostic signatures.

Authors:  Robert L Grubb; Jianghong Deng; Peter A Pinto; James L Mohler; Arul Chinnaiyan; Mark Rubin; W Marston Linehan; Lance A Liotta; Emanuel F Petricoin; Julia D Wulfkuhle
Journal:  J Proteome Res       Date:  2009-06       Impact factor: 4.466

Review 10.  Cancer associated fibroblasts in cancer pathogenesis.

Authors:  Omar E Franco; Aubie K Shaw; Douglas W Strand; Simon W Hayward
Journal:  Semin Cell Dev Biol       Date:  2009-11-05       Impact factor: 7.727

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.